Thinly traded micro cap AnaptysBio (ANAB -5.2%) is down, albeit on modest turnover of 42K shares, in reaction to preliminary results from a Phase 2 clinical, ECLIPSE, evaluating lead candidate etokimab in patients with chronic rhinosinusitis with nasal polyps.
At the week 8 time point, treatment with etokimab failed to show a significant treatment effect versus placebo as measured by bilateral nasal polyps score and sino-nasal outcome test, the primary endpoints.
The company will determine next steps for the program after reviewing 16-week data by year-end.
It is also developing the IL-33 inhibitor for the treatment of eosinophilic asthma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.